Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27493917 | 0.82 | CTSS (0.39) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL6929764 | 0.80 | CHRM3 (0.50) | CHRM3CHRM2CHRM1BPTFCXCR4 | |
| SCHEMBL7949007 | 0.80 | CTSS (0.37) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL13597048 | 0.80 | CYP1A2 (0.42) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL16226840 | 0.76 | CYP2B6 (0.41) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL4391647 | 0.76 | ALDH1A1 (0.49) | CHRM3ATML3MBTL1CYP2B6 | |
| SCHEMBL7368147 | 0.74 | CYP2B6 (0.43) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL7368148 | 0.74 | CYP2B6 (0.43) | CHRM3CHRM2CHRM1ATML3MBTL1 | |
| SCHEMBL10177756 | 0.72 | BPTF (0.55) | L3MBTL1BPTFCYP2D6 | |
| SCHEMBL6924076 | 0.72 | CHRM2 (0.50) | CHRM3CHRM2CHRM1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | CHRM3 125/4885CHRM2 1238/4885CHRM1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.